Lymph Node-Targeted
Delivery Platform
Many therapies fail due to poor targeting and toxicity.
Navicyte’s proprietary targeted drug delivery carrier technology mimics natural immune cell trafficking to deliver therapeutics directly to lymph nodes and immune-relevant tissues.
Key Benefits
A “Trojan Horse” delivery platform that mimics a cell to deliver immune-modulating drugs to critical tissue targets and expand the therapeutic index.
Precision Targeting: Reaches multiple lymph nodes after IV administration.
Dose Reduction: Up to 85% less drug needed to reach therapeutic thresholds.
Tunable Pharmacokinetics: Control release from hours to weeks.
Broad Payload Compatibility: Oncology drugs, vaccines, immunotherapies, nucleic acids.
Manufacturing Ready: FDA/GMP-compatible with existing CDMO pipelines.
Applications
Transforming therapeutics across diseases.
Oncology: Expands the therapeutic index of toxic chemotherapies (e.g., cisplatin) by over 500x, unlocking safer, more effective cancer treatments.
HIV & Tuberculosis: Accesses lymphoid reservoirs, enabling co-delivery of ARVs and LRAs to overcome treatment resistance.
Vaccines: Improves durability, reduces dose requirements, and enhances safety across global immunization programs.
Emerging Immunotherapies: Supports in situ CAR-T manufacturing and expands efficacy of immuno-modulatory drugs.
Market Opportunity
Building the future of drug delivery.
Immunotherapy and oncology are projected to surpass $1 trillion in global market value within the next decade.
Only ~10% of Phase I trials succeed — Navicyte helps de-risk this critical stage.
Our platform enables partners to rescue shelved compounds, enhance existing drugs, and accelerate breakthrough therapies.